Zacks: Analysts Expect INmune Bio, Inc. (NASDAQ:INMB) to Post -$0.23 EPS

Equities research analysts expect INmune Bio, Inc. (NASDAQ:INMB) to report earnings per share (EPS) of ($0.23) for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for INmune Bio’s earnings. INmune Bio posted earnings of ($0.19) per share during the same quarter last year, which suggests a negative year-over-year growth rate of 21.1%. The company is expected to report its next earnings report on Thursday, May 13th.

According to Zacks, analysts expect that INmune Bio will report full year earnings of ($1.03) per share for the current financial year. For the next financial year, analysts anticipate that the company will report earnings of ($1.48) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that follow INmune Bio.

INmune Bio (NASDAQ:INMB) last released its earnings results on Wednesday, March 3rd. The company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. The business had revenue of $0.01 million during the quarter.

A number of equities analysts recently issued reports on the company. Maxim Group restated a “buy” rating and issued a $13.00 target price on shares of INmune Bio in a report on Tuesday, February 9th. Zacks Investment Research raised INmune Bio from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Tuesday, March 9th. Five investment analysts have rated the stock with a buy rating, The stock presently has a consensus rating of “Buy” and a consensus target price of $18.40.

Institutional investors have recently made changes to their positions in the company. Ikarian Capital LLC bought a new position in INmune Bio during the fourth quarter worth $3,747,000. Point72 Asset Management L.P. bought a new stake in shares of INmune Bio during the third quarter valued at approximately $1,031,000. BlackRock Inc. raised its stake in shares of INmune Bio by 15.5% in the fourth quarter. BlackRock Inc. now owns 21,243 shares of the company’s stock valued at $366,000 after purchasing an additional 2,854 shares in the last quarter. Diametric Capital LP bought a new position in INmune Bio in the fourth quarter worth $215,000. Finally, Northern Trust Corp acquired a new stake in INmune Bio during the fourth quarter worth $213,000. Institutional investors and hedge funds own 7.38% of the company’s stock.

Shares of NASDAQ INMB traded up $0.19 during trading on Thursday, hitting $11.40. The company had a trading volume of 1,871 shares, compared to its average volume of 302,874. INmune Bio has a 52 week low of $3.31 and a 52 week high of $29.99. The business’s 50-day moving average is $15.01 and its 200 day moving average is $13.52. The company has a market cap of $170.24 million, a P/E ratio of -11.70 and a beta of 3.01.

INmune Bio Company Profile

INmune Bio, Inc, a clinical-stage immunotherapy company, focuses on reprogramming the patient's innate immune system to treat cancer Alzheimer's disease, and non-alcoholic steatohepatitis. The company intends to develop and commercialize product candidates to treat hematologic malignancies and solid tumors.

Further Reading: Dual Listing What You Need to Know

Get a free copy of the Zacks research report on INmune Bio (INMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for INmune Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for INmune Bio and related companies with MarketBeat.com's FREE daily email newsletter.